SpiceXpress signs agreement with B Medical Systems

IMT News Desk
IMT News Desk
· 2 min read
Historic Deal Panacea Biotec & Serum Institute of India

The agreement will help in reliable and temperature-controlled transportation of COVID-19 vaccine across India

SpiceXpress, the cargo arm of SpiceJet airline, signed an agreement with Luxembourg-based B Medical Systems for safe, reliable and temperature-controlled transportation of COVID-19 vaccine across India.

With an aim to expand the basket of COVID-19 vaccines and enhance the pace of inoculation in India, the central government had announced fast-track emergency approval for foreign-produced jabs that have been granted similar clearances in other countries.

The government’s move is significant as it may make available several vaccines, including those made by Pfizer, Moderna and Johnson & Johnson, in India with certain conditions.

In a statement, B Medical Systems said it will provide medical-grade transport solutions to SpiceXpress for the transportation of the COVID-19 vaccine and various pharmaceutical preparations across the country.

The transport boxes from B Medical Systems offer storage in the temperature range varying from -80°C to 8°C and are US FDA, EU MDR as well as WHO PQS certified, it noted.

“The collaboration also covers the opening of several pharma logistics centres of excellence across several airports in India,” it added.

The agreement between the two companies will facilitate safe, reliable and effective temperature-controlled transportation of vaccines, pharmaceutical preparation and various biological specimens across India, it stated. 

PTI

Read Next

Ministry of Ayush approves CoroQuil-Zn by Remedium Therapeutics
COVID-19
October 3, 2024

Ministry of Ayush approves CoroQuil-Zn by Remedium Therapeutics

The drug is enriched with potent herbs and zinc and offers a supportive approach to assist patients during their recovery from  COVID-19 The Ministry of Ayush, Government of India, recently approved CoroQuil-Zn, an herbal drug developed by Remedium Therapeutics in collaboration with Delhi Pharmaceutical Sciences and Research University, as an add-on treatment for mild and moderate […]
Article by: IMT News Desk
CrisprBits’ OmiCrisp tracks Omicron-derived JN.1 variant in sewage samples in Bengaluru
COVID-19
February 8, 2024

CrisprBits’ OmiCrisp tracks Omicron-derived JN.1 variant in sewage samples in Bengaluru

The test is currently being used to monitor sewage samples in 14 localities in Bengaluru Bengaluru-based startup CrisprBits has developed OmiCrisp, a CRISPR-based testing platform for rapid diagnosis and surveillance of SARS-CoV2. The CRISPR-based test not only detects the virus but also distinguishes variants of the Omicron lineage from other previously known variants of concern.  […]
Article by: IMT News Desk
Govt launches India’s first mRNA vaccine developed by Gennova
COVID-19
June 26, 2023

Govt launches India’s first mRNA vaccine developed by Gennova

GEMCOVAC -OM, an Omicron-specific mRNA-based booster vaccine has funding support from DBT & BIRAC Union Minister of State (Independent Charge) for Science and Technology, MoS PMO, Department of Atomic Energy and Department of Space and MoS Personnel, Public Grievances and Pensions, Dr Jitendra Singh launched the GEMCOVAC -OM, an Omicron-specific mRNA-based booster vaccine. India’s first […]
Article by: IMT News Desk
India’s first mRNA-based Omicron-specific booster vaccine from Gennova gets DCGI approval
COVID-19
June 21, 2023

India’s first mRNA-based Omicron-specific booster vaccine from Gennova gets DCGI approval

GEMCOVAC-OM is a lyophilised (freeze-dried) vaccine, stable at 2- 8 °C Pune-based Gennova Biopharmaceuticals announced that its mRNA COVID-19 booster vaccine – GEMCOVAC-OM – against the Omicron variant of SARS-CoV-2 received Emergency Use Authorization (EUA) from the office of the Drugs Controller General of India (DCGI). GEMCOVAC-OM is the first booster COVID-19 vaccine developed in India against […]
Article by: IMT News Desk